Share This


Acute renal colic is a common emergency condition, which can arise from a variety of underlying conditions that affect the urinary tract, but it is usually associated with the passage of ureteral stones. Before considering expectant management or active intervention, rapid and effective analgesia should be provided as initial treatment [1,2]. Observation and adjunctive pharmacological therapy can save the patient an invasive surgical intervention, as well as significant cost, but can also result in complications like infection and renal function deterioration [1,2].

Spontaneous stone passage and observation

Spontaneous passage of ureteral stones is influenced by multiple stone- and patient-related factors such as stone size, location, composition, ureteral anatomy, duration of obstruction, pain tolerance, infection and deterioration of renal function [1,2].

The majority of stones are expelled spontaneously within four to six weeks and stone passage rates increase with decreasing stone size [1,3]. Despite the limited data regarding spontaneous stone passage rates, the majority of stones <4mm, especially those located in the distal ureter, pass spontaneously within 40 days, and the proportion of patients needing early intervention increases with increasing stone size [2,4]. Therefore, observation with medical therapy and periodic follow-up may be an appropriate initial treatment for most patients with symptomatic ureteral stones <5mm with adequately controlled pain and absence of complications such as infection or renal function deterioration [1,2]. Conversely, active intervention is indicated for stones with low likelihood of spontaneous passage or which fail to pass within four weeks of initial observation, for persistent pain despite adequate analgesia and persistent obstruction with or without renal function damage [1,2,4].

Pain relief and fluid management

Adequate analgesia and hydration are the initial therapeutic step in patients with an acute stone episode. In the absence of contraindications, non-steroidal anti-inflammatory drugs (NSAIDs) such as diclofenac, indomethacin or ibuprofen, are recommended as first-line therapy [2]. Opioid analgesics have lower analgesic efficacy compared to NSAIDs and increased rate of adverse events, such as nausea and vomiting [2,5]. The addition of antispasmodics to NSAIDs is not superior to NSAIDs alone [6]. Except for pain relief, another important advantage of NSAIDs is their potential for reduction of recurrent renal colic episodes and hospital readmissions [7].

Renal colic is usually associated with nausea and vomiting which can lead to dehydration. As patients are often unable to tolerate oral liquids, intravenous hydration is an important adjunct to initial therapy. Traditionally, the treatment of patients with acute renal colic included aggressive oral or intravenous hydration to promote stone passage [8]. However, some authors failed to demonstrate a benefit of increased hydration for the spontaneous passage of ureteral stones and support minimal hydration to avoid volume depletion and exacerbation of renal colic [9,10]. A recent Cochrane review evaluated the advantages and disadvantages of diuretics and high volume hydration in conservative renal colic treatment, but found no reliable evidence to support their use due to the considerable risk of bias in the studies [11].

Medical expulsive therapy (MET)

The use of pharmacological agents to facilitate spontaneous stone passage is recommended as part of the routine expectant management of ureteral stones in patients with well controlled pain, no evidence of sepsis and adequate renal function reserve [1,2]. Various classes of drugs, such as α-adrenergic receptor blockers, calcium channel blockers, anticholinergics, corticosteroids, natural terpenes, influencing different pathophysiological mechanisms, have been investigated as MET. To date, α-blockers and calcium channel blockers have been evaluated extensively and are increasingly used as MET, although not licensed for this indication.

“The use of pharmacological agents to facilitate spontaneous stone passage is recommended as part of the routine expectant management of ureteral stones.”

The rationale for using α-adrenergic receptor blockers as MET is based on the detection of α-receptors in ureteral smooth muscle cells. Among the many α-adrenoceptor antagonists available, a number of randomised controlled studies have evaluated the efficacy and safety of tamsulosin, alfuzosin, doxasozin and terazosin in the expulsion of ureteral stones, suggesting a class effect [12-15]. Several meta-analyses have investigated the efficacy and safety of α-blockers and calcium channel blockers in ureteral stones and found an overall benefit for stone expulsion using an α-blocker or nifedipine compared to standard therapy or placebo control group [15-17]. However, a recently published randomised study on a large number of patients, reported no statistically significant differences in stone passage rates between tamsulosin, nifedipine and placebo and these findings were consistent across subgroups of stone size and location [18].

Anticholinergics, corticosteroids and natural terpenes have also been proposed as an adjunct to α-blocker therapy. The anti-inflammatory effect of corticosteroids to facilitate stone passage has been investigated in studies, which found that the addition of corticosteroid to α-blocker therapy offers a small benefit in stone expulsion [17,19]. The use of antimuscarinics is currently not recommended for MET as there is no additional benefit in stone passage rates either for tolterodine alone or in combination with tamsulosin [20]. Rowatinex® as a terpene combination has been shown to facilitate stone expulsion as a primary option or following shock wave lithotripsy (SWL) [21]. However, stone expulsion rates of Rowatinex® are inferior when compared to tamsulosin [22].

MET following SWL and ureteroscopy

MET is being widely used to assist the spontaneous passage of fragments following SWL of renal and ureteral stones. Systematic reviews of randomised trials suggested treatment benefit of adjuvant α-blockers on expulsion rates and expulsion time of fragments following SWL [16,23].

The use of MET following endourologic procedures has been shown to reduce renal colic episodes and improve stone-free rates [24]. Furthermore, several studies have demonstrated the beneficial effect of α-blockers and antimuscarinics on symptoms and quality of life of patients with indwelling ureteral stents following ureteroscopy [25].

Adverse events and duration of MET

The duration of MET ranges between two and four weeks and treatment is generally well tolerated [12-14]. Most adverse events are mild and reversible after discontinuation of medication and drop-out rates are very low [15,16].


The objectives of conservative treatment of renal colic are to provide analgesia and facilitate stone passage, while preventing recurrent pain episodes and complications from obstruction. Non-steroidal anti-inflammatory drugs (NSAIDs) are the recommended first-line treatment as they provide effective analgesia in acute renal colic. Currently available evidence suggests that MET, as a primary treatment option or following SWL, increases the spontaneous stone passage of ureteral stones <10mm. Even though the benefits of MET have been recently challenged by a large multicentre trial, further studies are required to confirm these results.



1. Preminger GM, Tiselius HG, Assimos DG, et al. EAU/AUA Nephrolithiasis Guideline Panel. 2007 Guideline for the Management of Ureteral Calculi. J Urol 2007;178(6):2418-34.
2. Türk C, Knoll T, Petrik A, et al; members of the European Association of Urology (EAU) Guidelines Office. Guidelines on Urolithiasis. Available at:
Accessed 7 Nov 2015.
3. Miller OF, Kane CJ. Time to stone passage for observed ureteral calculi: a guide for patient education. J Urol 1999;162:688.
4. Skolarikos A, Laguna MP, Alivizatos G, et al. The role for active monitoring in urinary stones: a systematic review. J Endourol 2010;24(6):923-30.
5. Holdgate A, Pollock T. Nonsteroidal anti-inflammatory drugs (NSAIDs) versus opioids for acute renal colic. Cochrane Database Syst Rev 2005;2:CD004137.
6. Afshar K, Jafari S, Marks AJ, et al. Nonsteroidal anti-inflammatory drugs (NSAIDs) and non-opioids for acute renal colic. Cochrane Database Syst Rev 2015;6:CD006027.
7. Laerum E, Ommundsen OE, Gronseth JE, et al. Oral diclofenac in the prophylactic treatment of recurrent renal colic. A double-blind comparison with placebo. Eur Urol 1995;28(2):108-11.
8. Phillips E, Kieley S, Johnson EB, et al. Emergency room management of ureteral calculi: current practices. J Endourol 2009;23(6):1021-4.
9. Springhart WP, Marguet CG, Sur RL, et al. Forced versus minimal intravenous hydration in the management of acute renal colic: a randomized trial. J Endourol 2006;20(10):713-6.
10. Albanis S, Ather HM, Papatsoris AG, et al. Inversion, hydration and diuresis during extracorporeal shock wave lithotripsy: does it improve the stone-free rate for lower pole stone clearance? Urol Int 2009;83(2):211-6.
11. Worster AS, Bhanich Supapol W. Fluids and diuretics for acute ureteric colic. Cochrane Database Syst Rev 2012;15:2.
12. De Sio M, Autorino R, Di Lorenzo G, et al. Medical expulsive treatment of distal-ureteral stones using tamsulosin: a single-center experience. J Endourol 2006;20(1):12-6.
13. Liatsikos EN, Katsakiori PF, Assimakopoulos K, et al. Doxazosin for the management of distal-ureteral stones. J Endourol 2007;21:538-41.
14. Yilmaz E, Batislam E, Basar MM, et al. The comparison and efficacy of 3 different a1-adrenergic blocker for distal ureteral stones. J Urol 2005;173:2010-2.
15. Campschroer T, Zhu Y, Duijvesz D, et al. Alpha-blockers as medical expulsive therapy for ureteral stones. Cochrane Database Syst Rev 2014;4:CD008509.
16. Seitz C, Liatsikos E, Porpiglia F, et al. medical therapy to facilitate the passage of stones: what Is the evidence? Eur Urol 2009;56(3):455-71.
17. Hollingsworth JM, Rogers MA, Kaufman SR, et al. Medical therapy to facilitate urinary stone passage: a meta-analysis. Lancet 2006;68:1171-9.
18. Pickard R, Starr K, MacLennan G, et al. Medical expulsive therapy in adults with ureteric colic: a multicentre, randomised, placebo-controlled trial. Lancet 2015;386(9991):341-9.
19. Porpiglia F, Vaccino D, Billia M. Corticosteroids and tamsulosin in the medical expulsive therapy for symptomatic distal ureter stones: single drug or association? Eur Urol 2006;50:339-44.
20. Erturhan S, Erbagci A, Yagci F, et al. Comparative evaluation of efficacy of use of tamsulosin and/or tolterodine for medical treatment of distal ureteral stones. Urology 2007;69:633-6.
21. Romics I, Siller G, Kohnen R, et al. Improving stone clearance after extracorporeal shock wave lithotripsy in urolithiasis patients by a special terpene combination (Rowatinex®): results of a placebo-controlled, randomized trial. Eur Urol Suppl 2010;9:819-25.
22. Aldemir M, Ucgul JE, Kayigil O. Evaluation of the efficiency of tamsulosin and rowanitex in patients with distal ureteral stones: a prospective, randomized, controlled study. Int Urol Nephrol 2011;43:79-83.
23. Schuler TD, Shahani R, Honey RJ, et al. Medical expulsive therapy as an adjunct to improve shockwave lithotripsy outcomes: a systematic review and meta-analysis. J Endourol 2009;23(3):387-93.
24. John TT, Razdan S. Adjunctive tamsulosin improves stone free rate after ureteroscopic lithotripsy of large renal and ureteric calculi: a prospective randomized study. Urology 2010;75(5):1040-2.
25. Papatsoris A, Dellis A, Daglas G, Sanguedolce F; EAU Young Academic Urology working parties (Endourology). Management of JJ stent-related symptoms. Acta Chir Iugosl 2014;61(1):73-4.

Declaration of competing interests: None declared.

Share This
Noor Buchholz

U-merge (Urology in Emerging Countries), London, UK; Sobeh’s Vascular and Medical Centre, Dubai Health Care City, Dubai, UAE.

View Full Profile
Kremena Petkova

U-merge (Urology in emerging countries), London, UK; Department of Urology and Nephrology, Military Medical Academy, Sofia, Bulgaria.

View Full Profile
Marcos Cepeda Delgado

U-merge (Urology in emerging countries), London, UK; University Department of Urology, Río Hortega University Hospital, Valladolid, Spain.

View Full Profile
Athanasios Papatsoris

U-merge (Urology in emerging countries), London, UK; University Department of Urology, Sismanoglio General Hospital, Athens, Greece.

View Full Profile